EIN 82-2120760

Odylia Therapeutics

IRS 501(c) type
501(c)(3)
Num. employees
5
State
Year formed
2017
Most recent tax filings
2022-12-01
Description
Odylia Therapeutics utilizes a unique, non-profit business model to accelerate the development of gene therapies from people with rare disease, changing the way treatments are brought from the lab to the clinic. The company is actively advancing drug development for rare diseases through its top three programs: rpgrip1 and ush1c gene therapy programs, and brydge solutions.
Total revenues
$1,098,401
2022
Total expenses
$866,473
2022
Total assets
$10,021,651
2022
Num. employees
5
2022

Program areas at Odylia Therapeutics

Advancing drug development for rare diseases. Odylia's top three programs are our rpgrip1 and ush1c gene therapy programs, and brydge solutions.

Who funds Odylia Therapeutics

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
Marin Community FoundationProgram Support$500,000
Usher 2020Research for Prevention of Usher Syndrome Blindness.$133,283
RDH12 Fund for SightResearch Grant$50,000
...and 5 more grants received

Personnel at Odylia Therapeutics

NameTitleCompensation
Ashley WinslowChief Executive Officer Cso$210,664
Susie Trotochaud, AbjDirector of Development
Jesse HoltDirector of Business Services
Susie TrotochaudSecretary$0

Financials for Odylia Therapeutics

RevenuesFYE 12/2022
Total grants, contributions, etc.$976,484
Program services$107,361
Investment income and dividends$14,556
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$0
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$1,098,401

Form 990s for Odylia Therapeutics

Fiscal year endingDate received by IRSFormPDF link
2022-122023-11-02990View PDF
2021-122022-11-15990View PDF
2020-122021-11-11990View PDF
2019-122021-02-17990View PDF
2018-122019-11-02990View PDF

Organizations like Odylia Therapeutics

OrganizationLocationRevenue
Phare BioBoston, MA$1,558,823
Social and Health Research CenterSan Antonio, TX$372,833
Associated Scientists To Help Minimize Allergies (ASTHMA)Seattle, WA$1,011,590
Brain Chemistry LabsJackson, WY$1,894,431
Pacific Health Research and Education InstituteHonolulu, HI$540,132
First Institute of All MedicinesMilford, DE$788,300
Whittemore Peterson InstituteReno, NV$290,630
Aurum Institute USANew York, NY$386,629
Dreyfus Health Policy and Research CenterNashville, TN$1,604,233
Prairie One SolutionsStillwater, OK$1,221,239
Data update history
January 23, 2024
Posted financials
Added Form 990 for fiscal year 2022
January 23, 2024
Updated personnel
Identified 3 new personnel
January 2, 2024
Used new vendors
Identified 1 new vendor, including
January 2, 2024
Received grants
Identified 2 new grant, including a grant for $133,283 from Usher 2020
October 22, 2023
Received grants
Identified 3 new grant, including a grant for $500,000 from Marin Community Foundation
Nonprofit Types
Medical research organizationsResearch centersCharities
Issues
Science and technologyHealth
Characteristics
Conducts researchTax deductible donations
General information
Address
1447 Peachtree St Ne
Atlanta, GA 30309
Metro area
Atlanta-Sandy Springs-Alpharetta, GA
Website URL
odylia.org/ 
Phone
(770) 842-9741
IRS details
EIN
82-2120760
Fiscal year end
December
Taxreturn type
Form 990
Year formed
2017
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
H00: Medical Research: General
NAICS code, primary
5417: Scientific Research and Development Services
Parent/child status
Independent
Free account sign-up

Want updates when Odylia Therapeutics has new information, or want to find more organizations like Odylia Therapeutics?

Create free Cause IQ account